PharmaCyte Biotech, Inc. (PMCB)
0.3422
0.00 (0.00%)
USD |
NASDAQ |
Oct 20, 16:00
0.3411
0.00 (0.00%)
After-Hours: 20:00
PharmaCyte Biotech Enterprise Value : -24.95M for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | -24.95M |
| October 19, 2026 | -24.95M |
| October 16, 2026 | -24.97M |
| October 15, 2026 | -24.79M |
| October 14, 2026 | -24.88M |
| October 13, 2026 | -24.80M |
| October 12, 2026 | -24.70M |
| October 09, 2026 | -24.28M |
| October 08, 2026 | -24.36M |
| October 07, 2026 | -24.27M |
| October 06, 2026 | -24.09M |
| October 05, 2026 | -24.44M |
| October 02, 2026 | -24.33M |
| October 01, 2026 | -24.29M |
| September 30, 2026 | -24.22M |
| September 29, 2026 | -24.13M |
| September 28, 2026 | -24.12M |
| September 25, 2026 | -23.89M |
| September 24, 2026 | -23.72M |
| September 23, 2026 | -24.02M |
| September 22, 2026 | -23.70M |
| September 21, 2026 | -23.78M |
| September 18, 2026 | -23.69M |
| September 17, 2026 | -24.07M |
| September 16, 2026 | -24.16M |
| Date | Value |
|---|---|
| September 15, 2026 | -24.52M |
| September 14, 2026 | -24.42M |
| September 11, 2026 | -23.79M |
| September 10, 2026 | -23.88M |
| September 09, 2026 | -23.52M |
| September 08, 2026 | -23.37M |
| September 04, 2026 | -23.40M |
| September 03, 2026 | -23.35M |
| September 02, 2026 | -23.46M |
| September 01, 2026 | -23.38M |
| August 31, 2026 | -23.25M |
| August 28, 2026 | -23.09M |
| August 27, 2026 | -22.82M |
| August 26, 2026 | -22.82M |
| August 25, 2026 | -22.83M |
| August 24, 2026 | -22.99M |
| August 21, 2026 | -22.90M |
| August 20, 2026 | -23.10M |
| August 19, 2026 | -22.91M |
| August 18, 2026 | -23.00M |
| August 17, 2026 | -22.80M |
| August 14, 2026 | -22.71M |
| August 13, 2026 | -22.72M |
| August 12, 2026 | -22.75M |
| August 11, 2026 | -22.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 538.25M |
| Amgen, Inc. | 280.61B |
| Anika Therapeutics, Inc. | 260.39M |
| BioCryst Pharmaceuticals, Inc. | 2.510B |
| Imunon, Inc. | 5.670M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.081M |
| Total Expenses (Quarterly) | 5.081M |
| EPS Diluted (Quarterly) | -0.5389 |
| Earnings Yield | -701.2% |
| Normalized Earnings Yield | -368.99 |